Cell Signaling Technology

Product Pathways - MAPK Signaling

Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (E10) Mouse mAb #9106

Applications Reactivity Sensitivity MW (kDa) Isotype
W IP IF-IC F H M R Mk Mi Pg Hm B Dm Z Endogenous 42, 44 Mouse IgG1kappa

Applications Key:  W=Western Blotting  IP=Immunoprecipitation  IF-IC=Immunofluorescence (Immunocytochemistry)  F=Flow Cytometry
Reactivity Key:  H=Human  M=Mouse  R=Rat  Mk=Monkey  Mi=Mink  Pg=Pig  Hm=Hamster  B=Bovine  Dm=D. melanogaster  Z=Zebrafish
Species cross-reactivity is determined by Western blot.

Protocols

Specificity / Sensitivity

Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (E10) Mouse mAb detects endogenous levels of p44 and p42 MAP Kinase (Erk1 and Erk2) when dually phosphorylated at Thr202 and Tyr204 of Erk1 (Thr185 and Tyr187 of Erk2), and singly phosphorylated at Tyr204. This antibody does not cross-react with the corresponding phosphorylated residues of either SAPK/JNK or p38 MAP kinase. This antibody may cross-react with an unknown cytoskeletal protein in some cell lines as visualized by immunofluorescence.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic phospho-peptide (KLH-coupled) corresponding to residues surrounding Thr202/Tyr204 of human p44 MAP kinase.

Western Blotting

Western Blotting

Specificity and sensitivity of the Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (E10) Mouse mAb: This antibody reacts specifically with as little as 50 pg of phosphorylated MAP kinase and does not cross-react with up to 4 µg of nonphosphorylated MAP kinase by Western blotting.

Western Blotting

Western Blotting

Western blot analysis of extracts from FGF treated SK-N-MC cells, using Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (E10) Mouse mAb (upper) or control p44/42 MAPK (Erk1/2) Antibody #9102 (lower).

Flow Cytometry

Flow Cytometry

Flow cytometric analysis of Jurkat cells, untreated (red) or PMA-treated (blue) ; and untreated (green) or PMA-treated (purple) following 90-minute CIP treatment, using Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (E10) Mouse mAb.


IF-IC

IF-IC

Confocal immunofluorescent images of Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (E10) Mouse mAb (green) and Phospho-Akt (Ser473) (193H12) Rabbit mAb #4058 (red) in C6 rat glioma cells treated with LPA as indicated. LPA induces cytoplasmic and nuclear phospho-p44/42 MAPK (Erk1/2) signal as well as cytoplasmic and membrane phospho-Akt signal. Addition of MEK inhibitor U0126 #9903 or PI3K inhibitor LY294002 #9901 completely blocks activation of phospho-p44/42 MAPK (Erk1/2) or phospho-Akt, respectively. Blue pseudocolor = DRAQ5™ (fluorescent DNA dye).

Background

Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines (1-3) and is an important target in the diagnosis and treatment of cancer (4). Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family as well as Mos and Tpl2/Cot. MEK1 and MEK2 are the primary MAPKKs in this pathway (5,6). MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK (7) and the transcription factor Elk-1 (8,9). p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs (10), along with MEK inhibitors such as U0126 and PD98059.

  1. Roux, P.P. and Blenis, J. (2004) Microbiol Mol Biol Rev 68, 320-44.
  2. Baccarini, M. (2005) FEBS Lett 579, 3271-7.
  3. Meloche, S. and Pouyssegur, J. (2007) Oncogene 26, 3227-39.
  4. Roberts, P.J. and Der, C.J. (2007) Oncogene 26, 3291-310.
  5. Rubinfeld, H. and Seger, R. (2005) Mol Biotechnol 31, 151-74.
  6. Murphy, L.O. and Blenis, J. (2006) Trends Biochem Sci 31, 268-75.
  7. Dalby, K.N. et al. (1998) J Biol Chem 273, 1496-505.
  8. Marais, R. et al. (1993) Cell 73, 381-93.
  9. Kortenjann, M. et al. (1994) Mol Cell Biol 14, 4815-24.
  10. Owens, D.M. and Keyse, S.M. (2007) Oncogene 26, 3203-13.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

This product is for in vitro research use only and is not intended for use in humans or animals. This product is not intended for use as therapeutic or in diagnostic procedures.

Products